NEPA Memory and Alzheimer’s Center
Sponsor: Danone Research
Indication: Mild to Moderate Alzheimer’s Disease
___________________________________________________________
Category: Mild to Moderate Alzheimer’s Disease
Title: A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer’s Disease using Alzheimer’s Disease Medication.
Summary: The primary objective to this study is to evaluate the effect of a nutritional drink on memory and thinking function compared to a control drink in people with mild to moderate-stage Alzheimer’s disease, who are using medication for their Alzheimer’s disease symptoms. A “control drink” is a liquid that tastes and looks like the nutritional drink, but does not contain any active ingredients.
Participants may be eligible to participate in this clinical research study for mild to moderate Alzheimer’s disease if the following criteria are met:
- Clinically diagnosed with mild-to-moderate Alzheimer’s Disease
- Taking an FDA approved medication for Alzheimer’s Disease (Aricept, Exelon, Razadyne, and/or Namenda) for the past 4 months
- 50 years of age or older
- Not previously diagnosed with vascular dementia, Huntington’s Disease, Parkinson’s Disease, or seizures
- Not living in a nursing home
- Able to have a caregiver or study partner be with you during all study visits and telephone calls
All study related visits, laboratory work, study medication, meals on assessment days, and all study related procedures are provided at no cost. Qualified participants will receive at no cost; study related physical exams, study medication, study-related laboratory tests and compensation for time and travel.
Principal Investigator: Mario Cornacchione, D.O.
Contact: Brenda Ferlenda, phone 570-262-0664
Location: Northeastern Pennsylvania Memory and Alzheimer’s Center,220 South